News Archive

Organizers of the $150K “Make Your Medical Device Pitch for Kids!” competition today announced the 12 finalists who are advancing to the live pitch component of the competition scheduled for Sept. 22 during the 7th Annual Pediatric Device Innovation Symposium hosted by Children’s National Health System. The pitch competition, sponsored by the National Capital Consortium for Pediatric Device Innovation (NCC-PDI), focuses on Neonatal Intensive Care Unit (NICU) innovations, a pediatric subspecialty that the Food and Drug Administration (FDA) identifies as having a significant unmet need for medical devices.

Making a therapeutic that contains biological components is just the start of creating a medicine. Then, biopharmaceutical companies must capture that drug and ensure that it’s free of contamination. New techniques and technologies can accomplish that capture and cleanup more simply and economically.

Bristol-Myers Squibb has allied with biotech accelerator BioMotiv. The deal sets Bristol-Myers up to found and fund biotechs with BioMotiv before going on to acquire them outright once a preclinical candidate is identified. 

REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, and Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, today announced an option and license agreement for exclusive worldwide rights to Clearside’s proprietary, in-office SCS Microinjector™ for the delivery of RGX-314 to the suprachoroidal space to treat wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and other conditions for which anti-vascular endothelial growth factor (anti-VEGF) treatment is currently the standard of care. REGENXBIO plans to evaluate RGX-314 using Clearside’s SCS Microinjector for in-office, non-surgical delivery into the suprachoroidal space, while continuing to advance its RGX-314 subretinal delivery program currently in development for wet AMD and DR.

Low interest rates and high stock valuations are fueling U.S. life sciences CEOs’ growing appetite for mergers and acquisitions, KPMG’s CEO Outlook found.

It’s a pivotal moment for the MedImmune spinout, which has put the fate of its first prospective product in regulators’ hands.

Biotech is booming across the country, especially in the top biotech clusters like Boston, San Francisco, New York and in the BioHealth Capital Region (BHCR). The global biotechnology market is expected to reach $775.2 billion by 2024 at a compound annual growth rate of 9.9 percent. 

Boosted by new research and development positions, Massachusetts last year experienced the fastest rate of biopharma job growth in a decade, according to a report released Tuesday from state trade group MassBio.

The agreement is intended to create a system for children with rare and complex health conditions.

In support of the U.S. government’s policy to maintain a stockpile to be able to protect every American from smallpox, Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract award by the Office of the Assistant Secretary for Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS) valued at approximately $2 billion over 10 years for the continued supply of ACAM2000®, (Smallpox (Vaccinia) Vaccine, Live) into the U.S. Strategic National Stockpile (SNS). The actual number of ACAM2000 doses to be procured is dependent on certain timing and tiered-pricing terms that are subject to the discretion of ASPR. ACAM2000 vaccine is the only vaccine licensed by the